Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin—A Randomized Placebo-Controlled Trial

Journal of Clinical Hypertension

Volumn 18, Issue 7, 2016, Pages 608-613

  Grübler, Martin R ^a,b   Gaksch, Martin ^a   Kienreich, Katharina ^a   Verheyen, Nicolas ^a   Schmid, Johannes ^a   Ó Hartaigh, Bríain W J ^c   Richtig, Georg ^a   Scharnagl, Hubert ^a   Meinitzer, Andreas ^a   Pieske, Burkert ^d   Fahrleitner Pammer, Astrid ^a   März, Winfried ^a,e   Tomaschitz, Andreas ^a,f   Pilz, Stefan ^a,g  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f Specialist Clinic for Rehabilitation Bad Aussee   (Austria)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PLACEBO; RENIN; THIAZIDE DIURETIC AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84978920115     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12825     Document Type: Article

References (32)

1. Kienreich K, Tomaschitz A, Verheyen N, et al. Vitamin D and cardiovascular disease. Nutrients. 2013;5:3005–3021.
2. Kienreich K, Grubler M, Tomaschitz A, et al. Vitamin D, arterial hypertension & cerebrovascular disease. Indian J Med Res. 2013;137:669–679.
3. Macdonald HM, Wood AD, Fraser WD, Simpson WG. Vitamin D status and ill health. Lancet Diabetes Endocrinol. 2014;2:e8–e9.
4. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33:456–492.
5. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97:1153–1158.
6. Solak Y, Covic A, Kanbay M. What do we know and do not know about vitamin D? A causal association between vitamin D receptor genetic polymorphism and hypertension. J Clin Hypertens (Greenwich). 2014;16:627–628.
7. Patel BM, Mehta AA. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol. 2012;697:1–12.
8. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006;114:2572–2574.
9. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch. 2009;458:231–246.
10. Donate-Correa J, Domínguez-Pimentel V, Muros-de-Fuentes M, et al. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease. Curr Drug Targets. 2014;15:703–709.
11. Zhou C, Lu F, Cao K, et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney Int. 2008;74:170–179.
12. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22:1603–1609.
13. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543–1551.
14. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–654.
15. Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010;21:966–973.
16. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010;411:1354–1360.
17. Pilz S, Gaksch M, Kienreich K, et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension. 2015;65:1195–1201.
18. Te Riet L, van Esch JH, Roks AJ, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960–975.
19. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–3281.
20. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
21. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219.
22. Grübler MR, Kienreich K, Gaksch M, et al. Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study. J Clin Hypertens (Greenwich). 2014;16:289–294.
23. Ó Hartaigh B, Gaksch M, Kienreich K, et al. Associations of daytime, nighttime, and 24-hour heart rate with four distinct markers of inflammation in hypertensive patients: the Styrian Hypertension Study. J Clin Hypertens (Greenwich). 2014;16:856–861.
24. Verheyen ND, Kienreich K, Gaksch M, et al. Plasma parathyroid hormone is independently related to nocturnal blood pressure in hypertensive patients: the Styrian Hypertension Study. J Clin Hypertens (Greenwich). 2016;18:543–550.
25. Carpenter JR, Goldstein H, Kenward MG. REALCOM-IMPUTE Software for multilevel multiple imputation with mixed response types. J Stat Softw http://www.jstatsoft.org/index.php/jss/article/view/v045i05. Accessed March 29, 2016.
26. Staessen JA, Birkenhäger W, Bulpitt CJ, et al. The relationship between blood pressure and sodium and potassium excretion during the day and at night. J Hypertens 1993;11:443–447.
27. Santos Rde S, Vieira da Costa VA, Vianna LM. Cholecalciferol treatment changes urinary sodium-potassium ratio and plasma aldosterone of spontaneously hypertensive rats. Clin Chim Acta. 2007;376:253–254.
28. Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A. 2008;105:15896–15901.
29. Schroten NF, Ruifrok WP, Kleijn L, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J. 2013;166:357–364.e2.
30. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850–2870.
31. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63:20–31.
32. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev. 2014;72:48–54.